The stock market closed higher on Tuesday as investors await progress on US-China trade talks and May’s consumer inflation report.
Overall, S&P 500 and NASDAQ were up 0.6% to 6,039 and 19,715, respectively.
Tweet of the Day
This is the reason why Fiserv $FI stock is in a downtrend: Clover volume growth slowed from 14% to 8% in just three months.
But now with a P/E of 16, the stock has good upside. https://t.co/s1xP9uDth7 pic.twitter.com/zKCxF5a4t1
— David Sharek (@GrowthStockGuy) June 6, 2025
Chart of the Day
Here is the ten-year chart of Eli Lilly (LLY) as of May 5, 2025, when the stock was at $821.
Patients who are taking Zepbound lost 20% of their body weight over 72 weeks compared to 14% for Wegovy. The trail also showed Zepbound helped patients lose 2 inches more around their waist than Wegovy.
Eli Lilly’s Mounjaro and Zepbound are Eli Lilly’s highest revenue producing drugs, with sales of both drugs more than doubling from last year. Last quarter, the weight loss drugs’, Mounjaro, revenue grew 113% year-over-year and the more recently released Zepbound’s sales increased 346%.
LLY is part of our Conservative Growth Portfolio, Growth Portfolio, and Aggressive Growth Portfolio. Looking ahead, a pill form of Zepbound, Orforglipron, could be a game changer for the industry, ushering in a slew of new patients who aren’t interested in injections.
